Vaark Ventures

Not surprising and very well deserved.

Too often, traditional healthcare treats symptoms instead of getting to the source of metabolic issues. At Hibiscus Health, we’re using facial analysis to pinpoint the root causes of diabetes and other metabolic conditions. By focusing on what’s happening at a metabolic level, our face-scanning technology provides personalized insights to help patients make sustainable changes and move towards better health. On Thursday I’m privileged to participate in a panel discussion on “Solving Healthcare Challenges by Looking at Root Cause.” I’m looking forward to sharing the insights we’ve gained through our research at Hibiscus Health. I am excited to learn from others in the industry who are reshaping healthcare through innovative care delivery. The Hibiscus Health Team and I are in Orlando this week, attending the Florida Association of ACOs (FLAACOs) Conference for the fifth year in a row! The conference is an incredible opportunity to connect with other innovators in the at-risk healthcare space, and we’re excited to share our face-scanning technology for cardiometabolic risk detection with other attendees! #PreventativeCare #EarlyDetection #MetabolicHealth #FLAACOs

A 2 min read this Friday as to why billion dollar corps fear Tele911.

It's World Diabetes Day... did you know a selfie could help detect your risk of diabetes? In this interview during #HLTH2024, we explore this revolutionary new approach to health screening with Kavi Misri, CEO & Founder of StartUp Health company Hibiscus Health. #HealthTransformer #HealthMoonshot #T1DMoonshot #WorldDiabetesDay ?? Watch on StartUp Health TV ?? https://ow.ly/Lx1650U6jti

ME.250.960.0001.FA24 The Role of Digital Health and the Health Care Delivery System is excited to hear from Alex Tang on Tuesday! Johns Hopkins Medicine The Johns Hopkins University School of Medicine CC Brent Stackhouse, Joe Mercado, Jessica R., M.S.

Any NYC metro area start-ups in deep tech should take a good look at Newlab and what they are doing in the Brooklyn Navy Yard. From rapid prototyping and design iteration to dry lab space and back office support, the energy of the place is palpable with enough rockets on the pad to make SpaceX jealous. Check it out! #technology #innovation

Tricky subject - how long should founder vesting schedules be? Let's start with the easy point: yes, ?????????? ?????????????? ?????????? ???? ???????? ?? ?????????????? ????????????????. It's very common for a founding team to split up at some point along the way in the first few years. If that departing founder walks away with a significant ownership stake (aka "dead equity") it will make future fundraising much more difficult, full stop. So how long should this founder vesting schedule be? Right now, a large majority of founders vest along a similar timeline to employees (4 year vest, though many founders do not have the 1-year cliff). There has been some movement towards 6-year vesting for founders though the shift has been fairly minor. If we overlay the vesting schedules against some data on time from incorporation to various fundraising stages, the potential issue becomes clear. 4 years into the company's life = a little beyond Series A, on median. Many companies will still be raising seed funding 4 years into the journey. Does it make sense for the founders to be fully vested when there's so much left to build? For many investors, the answer is no and they will insist on re-vesting founder equity (sometimes all, sometimes just in part) as a prerequisite to completing the round. This re-vesting is usually for another 4 years. ?????????? ???????????????????????????? ? The analogy to an employee isn't a great one for founders. Yes, if an employee stays 4 years they should get their full allotment of equity (you could make a case for longer periods here too). Often a company will re-incentivize great employees with a new grant at 3 years in order to maintain the retentive quality of equity. ?? ? Common objection from founders : "How is a departed founders equity any more dead weight than an angel or Seed investor that no longer adds any value?" Just my thinking here, but a) the value from the investor is mostly the capital itself and b) the departed founder often owns a bigger slice of pie. Also the impetus to revest is coming from investors that want you, the founder, to stick around for a long time after they put money in so it's not the same discussion. Not sure I have a perfect right answer, but I tend to think founders should vest over longer periods upfront. Open to pushback! #startups #founders #foundervesting #venturecapital More data on startups and the people who found them every Thursday morning in our Data Minute newsletter - subscribe here: https://lnkd.in/gNa_Dk-F

Vaark Ventures welcomes Dr. Chethan Sathya MD to the team. Dr. Sathya brings a wealth of knowledge and experience spanning corporate, academic, and government sectors and has led a number of healthcare coalitions addressing unmet social needs. His unique vantage point as a clinician, educator, and activist brings invaluable insight to our investment strategy and to our portcos. Welcome aboard, Che!

At the International Society for Pharmaceutical Engineering (ISPE) Annual Confrenece in Orlando, FL! Glad to see George Kwiecinski speak on an Analysis of Regulatory Data. Here’s to many more speeches, and a great continued confrence!

We are excited to share that Dr. Bon Ku will be speaking at our Today’s Healthcare Leaders Event on December 6th! He will be discussing, PARADIGM, a groundbreaking program dedicated to bringing hospital-level care to rural communities. He'll also highlight other research initiatives aimed at improving healthcare access and quality for underserved populations. Join us in exploring how we can bridge the healthcare gap. Register now to reserve your spot to get early bird pricing while it still lasts! https://lnkd.in/eg2cy5-X